𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lamivudine treatment for children with interferon refractory chronic hepatitis B

✍ Scribed by Nurten Koçak; İnci Nur Saltik; Hasan Özen; Aysel Yüce; Figen Gürakan

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
28 KB
Volume
31
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term lamivudine therapy for childre
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B
✍ Etienne M. Sokal; Deirdre A. Kelly; Jacek Mizerski; Isabel B. Badia; Jorge A. Ar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

One year of lamivudine treatment results in increased hepatitis B e antigen (HBeAg) seroconversion and serum hepatitis B virus (HBV) DNA negativity in children with chronic hepatitis B and high serum alanine aminotransferase concentrations. Two hundred seventy-six children who participated in a 1-ye

Comparison of interferon and lamivudine
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Masahiro Kobayashi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The aim of this study was to elucidate the long‐term outcome after interferon (IFN) or lamivudine (LMV) treatment in Japanese patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B. Inclusion criteria were biopsy proven chronic hepatitis or liver cirrhosis, no history

Adefovir-based combination therapy with
Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B
✍ Soon Sun Kim; Jae Youn Cheong; Dami Lee; Myoung Hee Lee; Sun Pyo Hong; Soo-Ok Ki 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

This study evaluated the efficacy of adefovir (ADV) plus lamivudine (LAM) or ADV add-on therapy for patients with entecavir (ETV)-refractory hepatitis B infection. Twenty-nine ETVresistant and 8 patients with suboptimal response to ETV were enrolled. Twenty-seven patients received ADV þ LAM therapy